Rapid antidepressant effect of addition of lithium to j tranylcypromine
FIGURE Structure of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Level 1 Level 2 Switch strategies Bupropion SR Sertraline Venlafaxine XR Level 2a Level 3 Switch strategies Nortriptyline Mirtazapine Level 4 Switch strategies Tranylcypromine
Level 1 Citalopram Level 2 Augmentation strategies Cognitive behavioral Cognitive Citalopram Citalopram + Citalopram + therapy + cognitive bupropion buspirone therapy Level 2a If unresponsive, switch to Bupropion SR Venlafaxine XR Level 3 Augmentation strategies Lithium augmentation T3 augmentation Level 4 Switch strategies Venlafaxine XR + mirtazapine
They include phenelzine (Nardil), isocarboxazid (Marplan) and tranylcypromine
Phenelzine (Nardil[R]), tranylcypromine
(Parnate[R]), isocarboxazid (Marplan[R]), and selegiline (Eldepryl[R]) are the MAOIs.
Behavioral alterations in response to fear-provoking stimuli and tranylcypromine
induced by perinatal exposure to bisphenol A and nonylphenol in male rats.
50] values (the concentration required to inhibit the metabolism of the surrogate substrates by 50%) were estimated then compared with those obtained for positive control inhibitory drugs (furafylline, sulfaphenazole, tranylcypromine
, quinidine, and ketoconazole).
and isoprocarboxazid are also used to treat
The Fatality Index (FTI) ranks amitryptyline (a TCAD) and tranylcypromine
as the two highest-ranking drugs with "unacceptable risks" of [greater than] 40 deaths per million prescriptions per year.
Miscellaneous: bupropion, tranylcypromine
Tricyclic antidepressants Amitriptyline Clomipramine Desipramine Doxepin Imipramine Nortriptyline Selective serotonin-reuptake inhibitors Fluoxetine Fluvoxam ine Paroxetine Sertraline Monoamine oxidase inhibitors Tranylcypromine
Phenelzine Others Alprazolam Amoxapine Bupropion Maprotiline Trazodone Lithium Table 2.
2) The Sequenced Treatment Alternatives to Relieve Depression (STARED) study demonstrated that <50% of MDD patients achieve remission in monotherapy trials of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, mirtazapine, or bupropion, necessitating consideration of antidepressant combinations, augmentation options, and eventually irreversible, nonselective MAOIs such as phenelzine, tranylcypromine
, or isocarboxazid.